Cartiva focuses on medical devices for treating osteoarthritis of the big toe. Credit: Al Kaissi et al.

Dutch medical device company Wright Medical Group has closed the acquisition of US-based orthopaedic devices maker Cartiva.

The company agreed to buy Cartiva for a total consideration of $435m in August this year. Cartiva primarily develops devices for the treatment of osteoarthritis of the great toe.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The acquisition bolsters Wright Medical’s Extremities business with the addition of Cartiva’s premarket approved technology called Synthetic Cartilage Implant (SCI) designed for high-volume foot and ankle procedures.

SCI is made of a biocompatible organic polymer that is durable with low friction. It can be implanted in approximately 35 minutes and is similar to natural cartilage in functionality.

“The acquisition bolsters Wright Medical’s Extremities business with the addition of Cartiva’s premarket approved technology called Synthetic Cartilage Implant (SCI) designed for high-volume foot and ankle procedures.”

The implant is said to reduce joint pain while retaining the foot’s natural movement, mobility and range of motion. This enables patients to return to their daily functions and activities faster than those treated through a fusion procedure.

Wright Medical Group president and CEO Robert Palmisano said: “With approximately 120,000 procedures for great toe arthritis performed each year in the US, we believe that this technology provides a proven alternative to fusion that reduces joint pain without sacrificing the foot’s natural movement and retains mobility and range of motion.”

In addition to the US, SCI has regulatory approvals in Canada, European Union (EU), Brazil, Chile and Australia.

Wright Medical is focussed on the development of extremities and biologics products. It offers surgical solutions for the upper and lower extremities and biologics markets.